Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Claire Long

- PMLiVE

Ipsen buys cancer business from stripped down Merrimack

Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval

Novartis building

Novartis boosts cardiovascular pipeline with $1bn Ionis deal

Gains rights to two lipoprotein-targeting drugs currently in early-stage clinical development 

Bayer promotes Robert LaCaze

He becomes EVP of new oncology strategic business unit

- PMLiVE

Novartis launches heart failure social network

Together in HF is the first digital effort of its kind for the condition

FDA: Cybersecurity is an ever-present risk for medical devices

US regulator issues new guidance for manufacturers

- PMLiVE

J&J partner drive nets 15 new deals, and another NASH drug

Fosters new collaborations in treatment-resistant depression, infectious diseases and cancer

- PMLiVE

Amgen wins block on sales of Sanofi/Regeneron’s Praluent

Repatha maintains patent rights but Sanofi and Regeneron set to appeal

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

- PMLiVE

Speaking the language of effective communications

Crafting appropriate communications still requires the fundamentals to be done brilliantly, but increasingly a smarter integrated approach is key, says Claire Gillis

- PMLiVE

Merck & Co’s Dr Daniel Pascheles joins Molekule Consulting

He becomes the biopharma services provider’s CEO

J&J collaborates on consumer health device accelerator

Partners with Shenzhen-based investor firm HAX

Celgene to apply machine learning to market access

Signs agreement for rights to GNS Healthcare's simulation platform

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links